This webinar aims to give learners a case-based exploration of hypercortisolism/Cushing Syndrome (CS) care, covering screening, diagnosis, referral, and treatment. It will closely examine how to identify and screen for atypical presentations of CS, as well as approaches to managing mild cases. The program will then build on these fundamentals by applying them to real-world treatment scenarios.
advertisement
Cushing's at the Core: Leading-Edge Strategies for Diagnosis and Medical Management of Cushing Syndrome
60 minutes
Share
Save
Restart
Resume
Share this program on:
Choose a format
Take Post-Test
Skip straight to the post-test if you have already participated in this activity.
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Related
Overview
Disclosure of Relevant Financial Relationships
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
Rosario Pivonello, MD, PhD (Planner/Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Corcept Therapeutics, Crinetics Pharmaceuticals, Lundbeck, and Recordati Rare Diseases, Inc.; Grant/Research Support: Corcept Therapeutics, Neurocrine Biosciences, Recordati Rare Diseases, Inc., Esteve Pharmaceuticals, Spruce Bioscience, and Xeris PharmaceuticalsAmir Hamrahian, MD (Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Crinetics Pharmaceuticals, Recordati Rare Diseases, Inc., Corcept Therapeutics, Cristcot; Grant/Research Support: Recordati Rare Diseases, Inc., Corcept Therapeutics, Lundbeck, AstraZeneca, Spruce Biosciences, Crinetics Pharmaceuticals; Data Monitoring Committee: Paradigm Biopharma
Honey East, MD (Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Amgen, Corcept Therapeutics, Regeneron; Grant/Research Support: Corcept Therapeutics, Novartis, Thermo Fisher Scientific; Speaker’s Bureau: Amgen, Corcept Therapeutics, Lilly
Off-Label Usage: This presentation includes discussion of off-label/investigational uses. The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or Cornerstone Medical Education. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Planners: American Academy of CME, Inc. and Cornerstone Medical Education have no relevant disclosures with ineligible companies.
Julia Shariff, MD (Reviewer) has no relevant relationships to disclose.
Target Audience
This educational initiative is targeted to the hypercortisolism/Cushing Syndrome (CS) care team, including endocrinologists, primary care physicians, cardiologists, nephrologists, and the interprofessional care team of advanced practice providers (nurse practitioners and physician assistants), nurses and pharmacists.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Review the guideline- and evidence-based screening and diagnostic strategies for Cushing Syndrome.
- Evaluate the need for referral to a specialist for Cushing Syndrome treatment.
- Summarize current treatment options for medical management of Cushing Syndrome in patients who are not surgical candidates, are awaiting a surgical consult, or prefer medical therapy over surgery.
- Collaborate as a team to design individualized, evidence-driven screening and medical management plans for patients with Cushing Syndrome, focusing on the role of the interprofessional and interdisciplinary team.
- Apply the principles of shared decision-making to real-world patient cases, focusing on screening, initial treatment and monitoring/follow-up of patients with Cushing Syndrome.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Cornerstone Medical Education. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physicians:
American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurse Practitioners and Nurses:
American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours (0.75 pharmacotherapeutic contact hours).Pharmacists:
This activity provides 1.0 ACPE contact hours (0.1 CEUs) of continuing education credit. UAN JA4008191-9999-26-046-H04-P, Knowledge.Physician Assistants:
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 5/29/2027. PAs should only claim credit commensurate with the extent of their participation.Other HCPs:
Other members of the care team will receive a certificate of participation.There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CNE credit for your participation, please complete the post-test and program evaluation.
Disclaimer
This activity is informational only and may encompass opinions of expert faculty that are based on real-world experience. Moreover, the educational session may make mention of published and/or investigational uses of therapeutics that are not yet approved by the FDA. In all cases, please refer to the latest FDA prescribing information for on-label clinical indications, warnings, adverse effect profiles, and/or contraindications for use in certain patient populations. The medical literature, and clinical practice as a whole, is constantly and rapidly evolving; as such, neither Cornerstone, the Academy or faculty are able to guarantee that the content presented herein will remain accurate beyond activity expiration (12 months from launch).
Provider(s)/Educational Partner(s)
Provided by Cornerstone Medical Education and AACME.
Commercial Support
Supported by an educational grant from Corcept Therapeutics.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Recommended
Details
Presenters
Related
Overview
This webinar aims to give learners a case-based exploration of hypercortisolism/Cushing Syndrome (CS) care, covering screening, diagnosis, referral, and treatment. It will closely examine how to identify and screen for atypical presentations of CS, as well as approaches to managing mild cases. The program will then build on these fundamentals by applying them to real-world treatment scenarios.
Disclosure of Relevant Financial Relationships
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
Rosario Pivonello, MD, PhD (Planner/Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Corcept Therapeutics, Crinetics Pharmaceuticals, Lundbeck, and Recordati Rare Diseases, Inc.; Grant/Research Support: Corcept Therapeutics, Neurocrine Biosciences, Recordati Rare Diseases, Inc., Esteve Pharmaceuticals, Spruce Bioscience, and Xeris PharmaceuticalsAmir Hamrahian, MD (Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Crinetics Pharmaceuticals, Recordati Rare Diseases, Inc., Corcept Therapeutics, Cristcot; Grant/Research Support: Recordati Rare Diseases, Inc., Corcept Therapeutics, Lundbeck, AstraZeneca, Spruce Biosciences, Crinetics Pharmaceuticals; Data Monitoring Committee: Paradigm Biopharma
Honey East, MD (Faculty) discloses the following relevant financial information with ineligible companies: Advisory Board/Consultant: Amgen, Corcept Therapeutics, Regeneron; Grant/Research Support: Corcept Therapeutics, Novartis, Thermo Fisher Scientific; Speaker’s Bureau: Amgen, Corcept Therapeutics, Lilly
Off-Label Usage: This presentation includes discussion of off-label/investigational uses. The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or Cornerstone Medical Education. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Planners: American Academy of CME, Inc. and Cornerstone Medical Education have no relevant disclosures with ineligible companies.
Julia Shariff, MD (Reviewer) has no relevant relationships to disclose.
Target Audience
This educational initiative is targeted to the hypercortisolism/Cushing Syndrome (CS) care team, including endocrinologists, primary care physicians, cardiologists, nephrologists, and the interprofessional care team of advanced practice providers (nurse practitioners and physician assistants), nurses and pharmacists.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Review the guideline- and evidence-based screening and diagnostic strategies for Cushing Syndrome.
- Evaluate the need for referral to a specialist for Cushing Syndrome treatment.
- Summarize current treatment options for medical management of Cushing Syndrome in patients who are not surgical candidates, are awaiting a surgical consult, or prefer medical therapy over surgery.
- Collaborate as a team to design individualized, evidence-driven screening and medical management plans for patients with Cushing Syndrome, focusing on the role of the interprofessional and interdisciplinary team.
- Apply the principles of shared decision-making to real-world patient cases, focusing on screening, initial treatment and monitoring/follow-up of patients with Cushing Syndrome.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Cornerstone Medical Education. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physicians:
American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurse Practitioners and Nurses:
American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours (0.75 pharmacotherapeutic contact hours).Pharmacists:
This activity provides 1.0 ACPE contact hours (0.1 CEUs) of continuing education credit. UAN JA4008191-9999-26-046-H04-P, Knowledge.Physician Assistants:
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 5/29/2027. PAs should only claim credit commensurate with the extent of their participation.Other HCPs:
Other members of the care team will receive a certificate of participation.There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CNE credit for your participation, please complete the post-test and program evaluation.
Disclaimer
This activity is informational only and may encompass opinions of expert faculty that are based on real-world experience. Moreover, the educational session may make mention of published and/or investigational uses of therapeutics that are not yet approved by the FDA. In all cases, please refer to the latest FDA prescribing information for on-label clinical indications, warnings, adverse effect profiles, and/or contraindications for use in certain patient populations. The medical literature, and clinical practice as a whole, is constantly and rapidly evolving; as such, neither Cornerstone, the Academy or faculty are able to guarantee that the content presented herein will remain accurate beyond activity expiration (12 months from launch).
Provider(s)/Educational Partner(s)
Provided by Cornerstone Medical Education and AACME.
Commercial Support
Supported by an educational grant from Corcept Therapeutics.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Title
Program Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?